Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, XS, Yan, X, Puchalski, T, Lonial, S, Lokhorst, HM, Voorhees, PM, Plesner, T, Liu, K, Khan, I, Jansson, R, Ahmadi, T, Ruixo, JJ Perez, Zhou, H, Clemens, PL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485722/
https://www.ncbi.nlm.nih.gov/pubmed/27859027
http://dx.doi.org/10.1002/cpt.577
Descripción
Sumario:New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen for daratumumab is challenging due to its target‐mediated drug disposition, leading to time‐ and concentration‐dependent pharmacokinetics. We describe a thorough evaluation of the recommended dose regimen for daratumumab in patients with relapsed or refractory MM.

Ejemplares similares